Virax Biolabs Files Form 6-K with SEC
Ticker: VRAX · Form: 6-K · Filed: Dec 17, 2024 · CIK: 1885827
| Field | Detail |
|---|---|
| Company | Virax Biolabs Group Ltd (VRAX) |
| Form Type | 6-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, reporting
TL;DR
Virax Biolabs just filed a routine 6-K with the SEC, no major news inside.
AI Summary
On December 17, 2024, Virax Biolabs Group Ltd. filed a Form 6-K, which is a report of foreign private issuers. This filing does not contain specific financial details or operational updates but serves as a notification to the SEC. The company is incorporated in E9 and has a fiscal year end of March 31.
Why It Matters
This filing indicates that Virax Biolabs Group Ltd. is fulfilling its reporting obligations as a foreign private issuer with the SEC, which is standard procedure for publicly traded companies outside the US.
Risk Assessment
Risk Level: low — The filing is a standard procedural report and does not contain any new material information that would inherently increase risk.
Key Numbers
- 001-41440 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- Virax Biolabs Group Ltd. (company) — Registrant
- 001-41440 (company) — SEC File Number
- 241553732 (company) — Film Number
- December 17, 2024 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the company has made or is required to make public pursuant to the laws of its home country, or that it has filed or will file with a stock exchange.
When was this Form 6-K filed?
This Form 6-K was filed on December 17, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH, United Kingdom.
What is Virax Biolabs Group Ltd.'s fiscal year end?
Virax Biolabs Group Ltd.'s fiscal year ends on March 31.
Does this filing indicate any new financial performance or operational updates?
No, this Form 6-K filing does not appear to contain specific financial performance figures or operational updates; it is a report of foreign private issuer information.
Filing Stats: 248 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-12-17 08:30:44
Filing Documents
- 6-k_shareholder_letter_d.htm (6-K) — 24KB
- vrax-ex99_1.htm (EX-99.1) — 27KB
- 0000950170-24-136922.txt ( ) — 52KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIRAX BIOLABS GROUP LIMITED Date: December 17, 2024 By: /s/ James Foster James Foster, Chief Executive Officer